A5088749175- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Urologic and reproductive health conditions
- Advanced Proteomics Techniques and Applications
- Glycosylation and Glycoproteins Research
- Cancer-related Molecular Pathways
- Renal and related cancers
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Carbohydrate Chemistry and Synthesis
- Cancer-related gene regulation
- Renal cell carcinoma treatment
- Pancreatic and Hepatic Oncology Research
- Galectins and Cancer Biology
- Hormonal and reproductive studies
Universidade de São Paulo
2018-2024
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2019-2022
Dr. Euryclides Hospital de Jesus Zerbini
2021
Abstract While aberrant protein glycosylation is a recognized characteristic of human cancers, advances in glycoanalytics continue to discover new associations between glycoproteins and tumorigenesis. This glycomics‐centric study investigates possible link paucimannosylation, an under‐studied class N ‐glycosylation [Man 1‐3 GlcNAc 2 Fuc 0‐1 ], cancer. The paucimannosidic glycans (PMGs) 34 cancer cell lines 133 tissue samples spanning 11 types matching non‐cancerous specimens are profiled...
The complexity and dynamics of the immensely heterogeneous glycoproteome prostate cancer (PCa) tumor microenvironment remain incompletely mapped, a knowledge gap that impedes our molecular-level understanding disease. To this end, we have used sensitive glycomics glycoproteomics to map protein-, cell-, grade–specific N- O-glycosylation in surgically removed PCa tissues spanning five histological grades (n = 10/grade) from patients with benign prostatic hyperplasia 5). Quantitative revealed...
Abstract The histology‐based Gleason score (GS) of prostate cancer (PCa) tissue biopsy is the most accurate predictor disease aggressiveness and an important measure to guide treatment strategies patient management. variability associated with PCa tumor sampling subjective determination GS are challenges that limit diagnostication prognostication. Thus, novel molecular signatures needed distinguish between indolent aggressive forms for better management outcomes. Herein, label‐free LC‐MS/MS...
specialists have an urge for biomarkers that can discriminate indolent prostate cancer from aggressive tumors. Ki67 is a proliferation marker, and its expression associated with the aggressiveness of several cancers.analyze in samples correlating disease.Ki67 mRNA levels were determined utilizing data TCGA cohort (Tumor(n)=492 control(n)=52). The protein was on 94 biopsies patients by immunohistochemical assay.in mRNA, upregulation tissue (p<0.0001) worst disease-free survival (p=0.035)....
Phospholipase A2 (PLA2) is a large family of enzymes involved in the inflammatory process that catalyzes hydrolysis membrane phospholipids, leading to production free fatty acids and lysophospholipids, starting arachidonic acid cascade. Their expression has been related behavior several cancers. Our objective search for PLA2 prostate cancer (PCa) tissue correlates with prognosis survival.
Abstract Purpose To assess the role of p160 family, AR, and AR-V7 in different initial presentations prostate cancer their association with clinical endpoints related to tumor progression. Methods The study sample comprises 155 patients who underwent radical prostatectomy 11 healthy peripheral zone biopsies as control group. Gene expression was quantified by qPCR from tissue specimens. statistical analysis investigated correlations between gene levels, associations disease presence,...
RESUMO Introdução: especialistas precisam biomarcadores que podem discriminar o câncer de próstata indolente tumores agressivos. Ki67 é um marcador proliferação, e sua expressão está associada à agressividade vários tumores. Objetivo: analisar a do em amostras correlacionando com da doença. Métodos: os níveis mRNA foram determinados utilizando dados uma coorte TCGA (Tumor(n)=492 controle(n)=52). A proteína foi determinada 94 biópsias pacientes por ensaio imuno-histoquímica. Resultados: no...
Partial nephrectomy is currently the gold standard treatment for renal tumors of up to 4 cm at their widest area.It has also been gaining support use on even larger around world.We report a case 74-year-old patient with an 11cm lesion right kidney associated left atrophy, which illustrates emerging worldwide trend performing nephron-sparing surgery patients T2 tumors.The underwent partial nephrectomy, then had favorable clinical evolution during follow-up period.Additionally, we present...